

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CELLTRION, INC.,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Inter Partes Review No.: IPR2023-00533

U.S. Patent No. 10,888,601 B2
Filed: April 29, 2019
Issued: January 12, 2021
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT
ANGIOGENIC EYE DISORDERS

**PETITION FOR *INTER PARTES* REVIEW
OF U.S. PATENT NO. 10,888,601 B2**

TABLE OF CONTENTS

	<u>Page</u>
TABLE OF AUTHORITIES	v
EXHIBIT LIST	xi
I. INTRODUCTION.....	1
II. MANDATORY NOTICES (37 C.F.R. § 42.8).....	3
A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(B)(1)).....	3
B. RELATED MATTERS (37 C.F.R. § 42.8(B)(2)).....	3
C. LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(B)(3)-(4)).....	5
III. PAYMENT UNDER 37 C.F.R. § 42.15(a) AND § 42.103.....	6
IV. GROUNDS FOR STANDING (37 C.F.R. § 42.104(a)).....	6
V. THRESHOLD REQUIREMENT FOR <i>INTER PARTES</i> REVIEW.....	6
VI. 35 U.S.C. §325(d) DISCRETIONARY DENIAL IS UNWARRANTED.....	6
VII. OVERVIEW OF PETITIONER’S CHALLENGES AND REQUESTED RELIEF.	11
A. STATUTORY GROUNDS OF CHALLENGE.	11
VIII. OVERVIEW OF THE ’601 PATENT.	12
IX. CLAIM CONSTRUCTION (37 C.F.R. § 42.104(b)(3)).....	14
A. “A METHOD FOR TREATING AN ANGIOGENIC EYE DISORDER IN A PATIENT IN NEED THEREOF” AND “A METHOD FOR TREATING AGE RELATED MACULAR DEGENERATION.”	15
1. The “method for treating” preamble is non-limiting, and does not require construction.	15

2.	Regeneron’s argument that the “method for treating” preamble is a positive limitation should be rejected.....	16
3.	If a limitation, the preamble’s plain and ordinary meaning—which does not provide any specific efficacy requirement— must govern.	18
B.	“INITIAL DOSE,” “SECONDARY DOSE,” AND “TERTIARY DOSE.”	21
C.	“WHEREIN EXCLUSION CRITERIA FOR THE PATIENT INCLUDE.”	22
1.	The Claimed Exclusion Criteria Are Entitled No Patentable Weight Under the Printed Matter Doctrine.....	22
X.	PERSON OF ORDINARY SKILL IN THE ART.	25
XI.	TECHNOLOGICAL BACKGROUND AND SCOPE AND CONTENT OF THE PRIOR ART.....	25
A.	VEGF TRAP-EYE/AFLIBERCEPT BACKGROUND.	26
B.	ANTI-VEGF THERAPY.	28
C.	EXCLUSION CRITERIA.....	29
D.	PETITIONER’S PRIOR ART REFERENCES.....	30
1.	Dixon (Ex.1006).....	30
2.	Adis (Ex.1007).....	33
3.	Regeneron (8-May-2008) (Ex.1013).	35
4.	NCT-795 (Ex.1014).	35
5.	’758 patent (Ex.1010).	37
6.	’173 patent (Ex.1008).	38
7.	Rosenfeld-2006 (Ex.1058).....	39
8.	Heimann-2007 (Ex.1040).	40
XII.	GROUND FOR UNPATENTABILITY—DETAILED ANALYSIS.	42

A.	ANTICIPATION.	42
1.	Legal standards.	42
2.	Ground 1: Dixon anticipates the Challenged Claims.	43
3.	Grounds 2, 3, and 4: Adis, Regeneron (8-May-2008), and NCT-795 anticipate the Challenged Claims.	50
B.	OBVIOUSNESS.....	58
1.	Legal standard.....	58
2.	Ground 5: The Challenged Claims are obvious over Dixon (either alone or in combination with the '758 patent or the '173 patent).	59
3.	Grounds 6 and 7: Claims 9 and 36 are obvious over Dixon in combination with Rosenfeld-2006 (Ground 6), or in combination with Heimann-2007 (Ground 7) (and if necessary, in combination with the '758 and '173 patents).	63
4.	No secondary considerations.	67
XIII.	CONCLUSION.....	69

TABLE OF AUTHORITIES

Page(s)

CASES

<i>Advanced Bionics, LLC v. Med-EL Elektromedizinische Geräte GmbH</i> , IPR2019-01469, 2020 WL 740292 (P.T.A.B. Feb. 13, 2020)	7, 10
<i>Amazon.com, Inc. v. M2M Sols. LLC</i> , IPR2019-01205, 2020 WL 448385 (P.T.A.B. Jan. 27, 2020)	8
<i>Amgen Inc. v. Alexion Pharms., Inc.</i> , IPR2019-00739, Paper 15 (P.T.A.B. Aug. 30, 2019)	8
<i>Amneal Pharms. LLC v. Alkermes Pharma Ireland Ltd.</i> , IPR2018-00943, Paper 8 (P.T.A.B. Nov. 7, 2018)	8
<i>Arctic Cat Inc. v. GEP Power Prods., Inc.</i> , 919 F.3d 1320 (Fed. Cir. 2019)	16
<i>Ariosa Diagnostics v. Verinata Health, Inc.</i> , 805 F.3d 1359 (Fed. Cir. 2015)	27
<i>Bayer Healthcare Pharms., Inc. v. Watson Pharms., Inc.</i> , 713 F.3d 1369 (Fed. Cir. 2013)	61
<i>Bayer Schering Pharma AG v. Barr Lab 'ys, Inc.</i> , 575 F.3d 1341 (Fed. Cir. 2009)	64
<i>Becton, Dickinson & Co. v. B. Braun Melsungen AG</i> , IPR2017-01586, Paper 8 (P.T.A.B. Dec. 15, 2017)	7, 9, 10
<i>Bio-Rad Lab 'ys, Inc. v. 10X Genomics Inc.</i> , 967 F.3d 1353 (Fed. Cir. 2020)	16
<i>Bristol-Myers Squibb Co. v. Ben Venue Lab 'ys, Inc.</i> , 246 F.3d 1368 (Fed. Cir. 2001)	16, 18, 44, 58
<i>Chengdu Kanghong Biotechnology Co. v. Regeneron Pharms., Inc.</i> , No. PGR2021-00035 (P.T.A.B.)	4
<i>Cubist Pharms., Inc. v. Hospira, Inc.</i> , 75 F. Supp. 3d 641 (D. Del. 2014)	57

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.